The KDM5D Knockout 143B Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the 143B human osteosarcoma cell line, engineered to disrupt the KDM5D locus. This product provides a loss-of-function model for the histone demethylase KDM5D, enabling dissection of its regulatory roles in chromatin remodeling and gene expression. The polyclonal nature preserves a heterogeneous pool of edited cells, capturing diverse mutation outcomes and avoiding potential biases associated with clonal selection. This format is well-suited for population-level functional genomics studies where the averaging effect of polyclonal editing reflects broader gene disruption consequences.
The host cell line, 143B, is a highly aggressive and metastatic human osteosarcoma model originally derived from the TE85 clone. These adherent, epithelial-like cells exhibit robust tumorigenicity and metastatic capacity in vivo, recapitulating key aspects of bone neoplasm biology. Their well-characterized genomics and stable growth properties make them a standard platform for investigating molecular drivers of osteosarcoma pathogenesis, metastasis, and drug response. Consequently, KDM5D knockout in this background offers a physiologically relevant system to study epigenetic contributions to bone cancer phenotypes.
KDM5D encodes a histone H3 lysine 4 demethylase that specifically removes di- and tri-methyl groups from H3K4me2/3, thereby mediating transcriptional repression. It functions as a co-repressor for the androgen receptor, modulating androgen-dependent gene expression programs by interacting with histone deacetylases HDAC1 and HDAC2. KDM5D activities intersect with chromatin-modifying complexes containing MLL1-4 methyltransferases, governing dynamic transitions between active (H3K4me2/3) and repressive chromatin states. Downstream, KDM5D regulates targets such as PSMA (FOLH1) and CDKN1A, linking androgen signaling to cell cycle control and metabolic adaptation.
In osteosarcoma, dysregulation of epigenetic modifiers is increasingly recognized as a driver of tumor progression and therapy resistance. Disruption of KDM5D in 143B cells permits direct interrogation of its role in histone methylation dynamics, androgen receptor co-repression, and transcriptional networks governing proliferation, migration, and survival. This knockout model is particularly valuable for assessing drug target candidates in androgen receptor-positive bone tumors or evaluating combinatorial strategies targeting chromatin regulators. Additionally, the loss-of-function context enables high-throughput screens and mechanistic studies delineating KDM5D-dependent pathways in a malignant bone microenvironment.
Researchers can employ this polyclonal knockout cell population in a wide array of experimental workflows, including ChIP-qPCR or immunofluorescence to assess H3K4me2/3 changes, western blotting and RT-qPCR for downstream target validation, cell proliferation and transwell migration assays for functional phenotyping, and RNA-seq or flow cytometry for transcriptome-wide or cell-cycle analyses. Applications span epigenetic regulation in osteosarcoma, androgen receptor signaling modulation, KDM5D functional studies in bone cancer, and drug target validation. For further technical specifications or order inquiries, please contact Ascent Research.
